Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Avecho Biotechnology Limited ( (AU:AVE) ) has provided an update.
Avecho Biotechnology Limited reported a significant increase in revenue by 79.4% to $560,069 for the half-year ended June 30, 2025, driven by research and development tax incentives. Despite this, the company experienced a 23% increase in losses, amounting to $2,675,960, due to higher expenses from ongoing operations, primarily attributed to a Phase III Clinical Trial for an oral cannabidiol capsule targeting insomnia. The company also reported a substantial net operating cash inflow of $4,532,100, bolstered by a $4,832,762 upfront licensing fee from Sandoz, which improved their working capital position.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited operates in the biotechnology industry, focusing on developing and commercializing pharmaceutical products. The company is involved in research and development, particularly in the area of oral drug delivery systems, with a market focus on improving the efficacy of pharmaceutical compounds.
Current Market Cap: A$22.21M
Find detailed analytics on AVE stock on TipRanks’ Stock Analysis page.